Figure S4.

Effects of imatinib on LGLs, MDSCs, and proliferations of naive and effector CD4⁺ and CD8⁺ T cells. (A) The frequencies (top) and the numbers (bottom) of NK (CD3⁻CD16⁺CD56^dimCD57⁺) and T (CD3⁺CD8⁺CD57⁺)-LGLs in the blood from CML patients in CMR (n = 21) or non-CMR (n = 20). (B) Frequency of granulocytic MDSCs (CD15⁺CD33⁺CD11b⁺HLA-DR⁻) and monocytic MDSCs (CD14⁺HLA-DR⁻) in the blood from CML patients in CMR (n = 23) or non-CMR (n = 20). (C) Frequency of CD11c⁺ MHC class II^high dendritic cells among CD3⁻ cells from PBMCs of CML patients in CMR or non-CMR (n = 8 each). (D) Expressions of CD86 and CD40 by dendritic cells from PBMCs of CML patients in CMR or non-CMR (n = 8 each). Analyses were performed in patients from whom sufficient numbers of PBMCs were available. MFI, mean fluorescence intensity. (E and F) Proliferations of naive and effector subsets of CD4⁺ (E) and CD8⁺ (F) T cells prepared from PBMCs of healthy donors. Cells were stimulated with anti-CD3 and anti-CD28 mAbs with graded doses of imatinib (n = 5 each) for 5 d and assessed by CFSE dilution. CCR7⁺CD45RA⁺ as naive, CCR7⁺CD45RA⁻ as central memory (CM), and CCR7⁻CD45RA⁻ as effector memory (EM) T cells. (G and H) Effects of imatinib on cytokine production. CD8⁺ T cells from PBMCs of healthy donors (n = 6) were stimulated with PMA and ionomycin with graded doses of imatinib, and cytokine production was assessed by intracellular cytokine staining; IFN-γ and/or TNFα (G), and IFN-γ and/or IL-2 (H). Data are pooled from at least two independent experiments. Horizontal lines indicate medians in A–C. Statistical significance was assessed by Mann-Whitney U test in A–D or by two-way ANOVA with Holm-Sidak multiple comparisons to CD4⁺ T cells in E, CD8⁺ T cells in F, or each cytokine at 0 µM imatinib dose in G and H. Error bars indicate means ± SEM in D–H. ns, not significant; *, P < 0.05.